Bone Health and Bone-Targeted Therapies for Prostate Cancer

For men with nonmetastatic prostate cancer at high risk of fracture receiving androgen deprivation therapy (ADT), denosumab at the osteoporosis-indicated dosage should be considered to reduce the risk of fracture. In situations or jurisdictions where denosumab is contraindicated or not available, a bisphosphonate is a reasonable option.